Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266189 | 0.96 | HTT (0.43) | HTTSMN1; SMN2TDP1L3MBTL1LMNA | |
| SCHEMBL13328975 | 0.93 | HTT (0.45) | HTTSMN1; SMN2TDP1L3MBTL1BCHE | |
| SCHEMBL13602257 | 0.90 | HTT (0.43) | HTTSMN1; SMN2TDP1L3MBTL1LMNA | |
| SCHEMBL13329235 | 0.86 | HTT (0.40) | HTTSMN1; SMN2TDP1L3MBTL1BCHE | |
| SCHEMBL13167686 | 0.83 | BCHE (0.51) | HTTSMN1; SMN2TDP1L3MBTL1LMNA | |
| SCHEMBL13243767 | 0.81 | HSD11B1 (0.37) | HTTSMN1; SMN2TDP1L3MBTL1BCHE | |
| SCHEMBL13602273 | 0.80 | MCL1 (0.35) | HTTSMN1; SMN2TDP1HSD11B1MAPT | |
| SCHEMBL822840 | 0.80 | HTT (0.70) | HTTSMN1; SMN2TDP1L3MBTL1MAPT | |
| SCHEMBL13181443 | 0.78 | MCL1 (0.45) | HTTSMN1; SMN2LMNAHSD11B1MAPT | |
| SCHEMBL14364714 | 0.78 | HTT (0.38) | HTTSMN1; SMN2TDP1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | HTT 2006/4885SMN1; SMN2 4123/4885TDP1 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.